Vol 2012, No 1 (2012)

January 2012

Table of Contents

Research & Development

Reata Pharmaceuticals Partners Again with Abbott for US$400 M Upfront Abstract
Heather Cartwright
Baxter and Momenta Form Global Collaboration to Develop and Commercialise Biosimilars Abstract
Heather Cartwright
Karo Bio and Pfizer Form Research Collaboration to Discover and Develop ROR-Gamma Modulators Abstract
Heather Cartwright

Licensing

Amgen Enters Biosimilars Market with Watson Pharmaceuticals Collaboration Abstract
Heather Cartwright
Pharmacyclics Signs US$975 M Agreement with Janssen Biotech for Mid-Stage Btk Inhibitor Abstract
Heather Cartwright
Merck & Co. Licenses Exelixis’ PI3K-Delta R&D Programme Abstract
Heather Cartwright
AstraZeneca Signs Two Deals to Reinforce its Pipeline After Development Setbacks Abstract
Heather Cartwright
Biogen Idec Options Isis Pharmaceuticals’ Antisense Drug for Spinal Muscular Atrophy Abstract
Heather Cartwright

Mergers & Acquisitions

Prestige Brands Agrees to Buy GSK’s Non-Core North American OTC Brands Abstract
Heather Cartwright
Takeda to Gain Selective PI3K and mTOR Inhibitors via Intellikine Acquisition Abstract
Heather Cartwright
BMS Adds Nucleotide Analogue to its HCV Pipeline with US$2.5 B Inhibitex Acquisition Abstract
Heather Cartwright

Cartoons

Decision Maker Abstract jpg
Clive Goddard

Features

Benchmarking – A Market Approach to Valuation Abstract
Nigel Borshell

Technology Access

Eli Lilly Joins ImmunoGen’s List of Big Pharma Collaborators Abstract
Heather Cartwright

Opinion & Analysis

ANNUAL REVIEW: Deal Making in 2011 Abstract
Heather Cartwright


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.